Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical trial seeking a treatment for depression which has failed to meet its primary endpoint. In our fast-paced world, balancing a busy work schedule with life’s inevitable ups and downs can be challenging. Drugs for cognitive
Read More
With mixed quarter results for the June quarter, Holista Colltech (ASX: HCT) – a research-driven biotech company, is trying to stay afloat amidst challenges. Dedicated to developing and commercialising innovative food products, the Perth based company has seen a decline of 3.7% in overall sales receipts. With a focus on natural ingredients the company has
Read More
A new drug seeking to treat irritability associated with Autism Spectrum Disorder (ASD) could soon be making its way to clinical trials in healthy volunteers after Zelira Therapeutics (ASX: ZLD) concluded a positive round of discussions with the United States Food and Drug Administration (FDA) on a study design. The proposed clinical trials are for
Read More
Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility Empax Centre. The centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics. The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen
Read More
Biotech company Arovella Therapeutics (ASX: ALA), focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, has achieved a major milestone. It has completed process development for its patent-protected manufacturing process required for large-scale Good Manufacturing Practice (GMP) manufacturing of its lead product, ALA-101. ALA-101 is an “off-the-shelf” CAR-iNKT cell
Read More
Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More